Cover Image
市場調查報告書

Incyte Corporation:產品平台分析

Incyte Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224631
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
Incyte Corporation:產品平台分析 Incyte Corporation - Product Pipeline Review - 2016
出版日期: 2016年05月31日 內容資訊: 英文 84 Pages
簡介

Incyte Corporation是從事腫瘤及發炎性疾病領域治療用小分子的藥物研究與開發的生物醫藥品企業。

本報告提供Incyte Corporation的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Incyte Corporation的基本資料

Incyte Corporation概要

  • 主要資訊
  • 企業資料

Incyte Corporation:R&D概要

  • 主要的治療範圍

Incyte Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Incyte Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

Incyte Corporation:藥物簡介

  • ruxolitinib phosphate
  • INCB-047986
  • INCB-24360
  • INCB-39110
  • 慢性性的適合發炎狀態的治療藥
  • 癌症治療藥
  • INCB-040093
  • INCB-050465
  • 適合發炎性疾病的小分子

Incyte Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Incyte Corporation:最近的開發平台趨勢

Incyte Corporation:暫停中的計劃

Incyte Corporation:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • aderbasib
    • INCB-15050
    • INCB-8696
    • INCB-9471

Incyte Corporation:企業發表

Incyte Corporation:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08061CDB

Summary

Global Markets Direct's, 'Incyte Corporation - Product Pipeline Review - 2016', provides an overview of the Incyte Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Incyte Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Incyte Corporation
  • The report provides overview of Incyte Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Incyte Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Incyte Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Incyte Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Incyte Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Incyte Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Incyte Corporation Snapshot
    • Incyte Corporation Overview
    • Key Information
    • Key Facts
  • Incyte Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Incyte Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Incyte Corporation - Pipeline Products Glance
    • Incyte Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Incyte Corporation - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Incyte Corporation - Drug Profiles
    • (INCB-039110 + INCB-040093)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epacadostat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-40093
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • itacitinib adipate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ruxolitinib phosphate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-50465
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-52793
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-53914
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-54329
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-54828
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-59872
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHR-1210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCAGN-1876
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCAGN-1949
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INCB-57643
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TIM3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Chronic Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Incyte Corporation - Pipeline Analysis
    • Incyte Corporation - Pipeline Products by Target
    • Incyte Corporation - Pipeline Products by Route of Administration
    • Incyte Corporation - Pipeline Products by Molecule Type
    • Incyte Corporation - Pipeline Products by Mechanism of Action
  • Incyte Corporation - Recent Pipeline Updates
  • Incyte Corporation - Dormant Projects
  • Incyte Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • aderbasib
      • INCB-047986
      • itacitinib adipate
      • ruxolitinib phosphate
  • Incyte Corporation - Company Statement
  • Incyte Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Incyte Corporation, Key Information
  • Incyte Corporation, Key Facts
  • Incyte Corporation - Pipeline by Indication, 2016
  • Incyte Corporation - Pipeline by Stage of Development, 2016
  • Incyte Corporation - Monotherapy Products in Pipeline, 2016
  • Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016
  • Incyte Corporation - Partnered Products in Pipeline, 2016
  • Incyte Corporation - Partnered Products/ Combination Treatment Modalities, 2016
  • Incyte Corporation - Out-Licensed Products in Pipeline, 2016
  • Incyte Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Incyte Corporation - Phase II, 2016
  • Incyte Corporation - Phase I, 2016
  • Incyte Corporation - IND/CTA Filed, 2016
  • Incyte Corporation - Preclinical, 2016
  • Incyte Corporation - Discovery, 2016
  • Incyte Corporation - Pipeline by Target, 2016
  • Incyte Corporation - Pipeline by Route of Administration, 2016
  • Incyte Corporation - Pipeline by Molecule Type, 2016
  • Incyte Corporation - Pipeline Products by Mechanism of Action, 2016
  • Incyte Corporation - Recent Pipeline Updates, 2016
  • Incyte Corporation - Dormant Developmental Projects,2016
  • Incyte Corporation - Discontinued Pipeline Products, 2016
  • Incyte Corporation, Subsidiaries

List of Figures

  • Incyte Corporation - Pipeline by Top 10 Indication, 2016
  • Incyte Corporation - Pipeline by Stage of Development, 2016
  • Incyte Corporation - Monotherapy Products in Pipeline, 2016
  • Incyte Corporation - Combination Treatment Modalities in Pipeline, 2016
  • Incyte Corporation - Partnered Products in Pipeline, 2016
  • Incyte Corporation - Out-Licensed Products in Pipeline, 2016
  • Incyte Corporation - Pipeline by Top 10 Target, 2016
  • Incyte Corporation - Pipeline by Route of Administration, 2016
  • Incyte Corporation - Pipeline by Molecule Type, 2016
  • Incyte Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top